メインのコンテンツにスキップする

申し訳ございませんが、お客様のブラウザには完全に対応しておりませんオプションがありましたら、新しいバージョンにアップグレードするか、 Mozilla Firefox、 Microsoft Edge、Google Chrome、またはSafari 14以降をお使いください。これらが利用できない場合、またサポートが必要な場合は、フィードバックをお送りください。

この新ホームページへのフィードバックを歓迎します。ご意見をお寄せください 新しいタブ/ウィンドウで開く

Elsevier
論文を投稿する

Profile

Florian Krammer

FK

Florian Krammer

Icahn School of Medicine at Mount Sinai, USA

Florian Krammer, PhD, graduated from the University of Natural Resources and Life Sciences, Vienna. He received his postdoctoral training in the laboratory of Dr. Peter Palese at the Icahn School of Medicine at Mount Sinai, New York working on hemagglutinin stalk-based immunity and universal influenza virus vaccines. In 2014, he became an independent principal investigator and is currently the endowed Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai. He is also the co-director of the Center for Vaccine Research and Pandemic Preparedness (C-VaRPP). Furthermore, since 2024, Dr. Krammer is Professor for Infection Medicine at the Ignaz Semmelweis Institute at the Medical University of Vienna. Dr. Krammer's work focuses on understanding the mechanisms of interactions between antibodies and viral surface glycoproteins and on translating this work into novel, broadly protective vaccines and therapeutics. The main target is influenza virus but he is also working on coronaviruses, flaviviruses, hantaviruses, filoviruses and arenaviruses. He has published more than 400 papers on these topics. Since 2019, Dr. Krammer serves as principal investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC), which develops improved seasonal and universal influenza virus vaccines that induce long-lasting protection against drifted seasonal, zoonotic and future pandemic influenza viruses. Finally, Dr. Krammer is an elected fellow of the American Academy of Microbiology and the Henry Kunkel Society, he is on the Board of Directors of the European Scientific Working Group on Influenza (ESWI) and he serves as one of the chairs of the SAVE group which tracks SARS-CoV-2 variants for the US NIH.